Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046401 | 1.00 | NPSR1 (0.46) | NPSR1KMT2AMEN1TSHRPOLB | |
| SCHEMBL3697118 | 0.84 | HDAC4 (0.54) | KMT2AMEN1TSHRPOLBNPC1 | |
| SCHEMBL3705072 | 0.84 | HDAC4 (0.54) | KMT2AMEN1TSHRPOLBNPC1 | |
| SCHEMBL995119 | 0.77 | POLB (0.66) | NPSR1KMT2AMEN1POLBNPC1 | |
| SCHEMBL27900169 | 0.76 | KMT2A (0.65) | NPSR1KMT2AMEN1TSHRPOLB | |
| SCHEMBL28801747 | 0.76 | CHRNA7 (0.57) | NPSR1KMT2AMEN1TSHRPOLB | |
| SCHEMBL17559449 | 0.74 | KMT2A (0.54) | NPSR1KMT2AMEN1TSHRPOLB | |
| SCHEMBL3694633 | 0.74 | ESR2 (0.50) | KMT2ATSHRCRBNNPC1TP53 | |
| SCHEMBL13163346 | 0.74 | ESR2 (0.50) | KMT2ATSHRCRBNNPC1TP53 | |
| SCHEMBL3703059 | 0.74 | ESR2 (0.50) | KMT2ATSHRCRBNNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | disclosed |
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | CASR, SARAF, ORAI1 | NPSR1 90/4885KMT2A 4730/4885MEN1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.